Answers are grounded in this paper and cite their sources.
Objectives Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited therapeutic options. This study investigated the antifibrotic effects and underlying mechanisms of anlotinib in bleomycin-induced pulmonary fibrosis. Methods C57BL/6 mice received intranasal bleomycin and were treated with anlotinib or nintedanib for 21 days. Lung inflammation, fibrosis, oxidative stress, epithelial–mesenchymal transition (EMT) -associated protein expression, and growth factor expression were evaluated. Transcriptomic analysis was performed on lung tissues. Human fetal lung fibroblasts (HFL1) were treated with bleomycin and subjected to pharmacological inhibition or genetic manipulation of the integrin β3/FAK pathway. Results Anlotinib attenuated bleomycin-induced pulmonary inflammation, collagen deposition, and fibrosis-associated changes. In the comparative treatment cohort, both anlotinib (6 mg/kg) and nintedanib (60 mg/kg) reduced histological inflammation and fibrosis scores under the experimental conditions investigated. Transcriptomic analysis identified focal adhesion and ECM–receptor interaction as key regulated pathways. In HFL1 cells, inhibition of integrin β3 or Focal adhesion kinase (FAK) suppressed α-SMA, collagen I, fibronectin 1 expression, and cell migration, whereas FAK or MEK1 overexpression reversed these effects. Conclusion Anlotinib attenuates bleomycin-induced pulmonary fibrosis, with integrin β3/FAK/MAPK-associated signaling potentially contributing to its antifibrotic effects.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: